Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
Public ClinicalTrials.gov record NCT05640102. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 4, Observational Study Evaluating the Efficacy and Safety of the Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Patients With Waldenström Macroglobulinemia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a hybrid (retrospective and prospective) non-interventional registry study to further describe the clinical profile of zanubrutinib in Waldenström macroglobulinemia (WM) participants with and without specific mutations and from racial and ethnic minority groups. Data collected from this registry study will be used to better understand the clinical benefit and safety of zanubrutinib for the treatment of participants in these populations.
Study identification
- NCT ID
- NCT05640102
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2, 2023
- Primary completion
- Nov 30, 2026
- Completion
- Nov 30, 2027
- Last update posted
- Aug 6, 2026
2023 – 2027
United States locations
- U.S. sites
- 7
- U.S. states
- 4
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute | Huntsville | Alabama | 35805-2606 | Recruiting |
| South Alabama Medical Science Foundation Mitchell Cancer Institute | Mobile | Alabama | 36604-1405 | Recruiting |
| City of Hope National Medical Center | Duarte | California | 91010-3012 | Recruiting |
| Los Angeles Cancer Network (Lacn) | Glendale | California | 91204-3640 | Recruiting |
| Eisenhower Medical Center, Lucy Curci Cancer Center | Rancho Mirage | California | 92270-3221 | Recruiting |
| Hattiesburg Hematology and Oncology Clinic | Hattiesburg | Mississippi | 39401-7233 | Active, not recruiting |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89169-3321 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Waldenstrom Macroglobulinemia trials
Other public records listing Waldenstrom Macroglobulinemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT07711327: Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy Not yet recruiting
- NCT06860880: Combating Cancer-Related Fatigue: A Personalized Supportive Care Program Recruiting
- NCT07231952: A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Recruiting
- NCT05190705: Loncastuximab Tesirine in WM Active, not recruiting
- NCT04840602: Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Recruiting
- NCT07101328: A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05640102, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 6, 2026 · Synced Sep 15, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05640102 live on ClinicalTrials.gov.